Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Registrati

CPRX Catalyst Pharmaceuticals Inc

23,8589

-0,3911 (-1,61%)

02 Apr 2025 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

03/03/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Brian Elsbernd

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Catalyst Pharmaceuticals (NASDAQ:CPRX)
Storico
Da Mar 2025 a Apr 2025

Clicca qui per i Grafici di Catalyst Pharmaceuticals

Grafico Azioni Catalyst Pharmaceuticals (NASDAQ:CPRX)
Storico
Da Apr 2024 a Apr 2025

Clicca qui per i Grafici di Catalyst Pharmaceuticals

Notizie Catalyst Pharmaceuticals Inc - CPRX

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 5 Marzo 2025 (4 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 5 Marzo 2025 (4 settimane fa) • Edgar (US Regulatory)

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
Martedì 4 Marzo 2025 (4 settimane fa) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Lunedì 3 Marzo 2025 (4 settimane fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Lunedì 3 Marzo 2025 (4 settimane fa) • Edgar (US Regulatory)

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
Venerdì 28 Febbraio 2025 (1 mese fa) • Edgar (US Regulatory)

Form 8-K - Current report
Mercoledì 26 Febbraio 2025 (1 mese fa) • Edgar (US Regulatory)

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Mercoledì 26 Febbraio 2025 (1 mese fa) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mercoledì 26 Febbraio 2025 (1 mese fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 19 Febbraio 2025 (1 mese fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 19 Febbraio 2025 (1 mese fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 19 Febbraio 2025 (1 mese fa) • Edgar (US Regulatory)

Più Catalyst Pharmaceuticals Inc Articoli Notizie

BlackRock Institutional ...

BlackRock Institutional ...

Hamilton Beach Brands

BNP Paribas Issuance

First Trust Cloud Comput...

Euronext Safran Decremen...

BNP Paribas Issuance

Delayed Upgrade Clock

Assistenza: support@advfn.it

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni